<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887012</url>
  </required_header>
  <id_info>
    <org_study_id>IR2021002168</org_study_id>
    <nct_id>NCT04887012</nct_id>
  </id_info>
  <brief_title>Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL</brief_title>
  <official_title>Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of HLA haploidentical CAR-NK cells targeting CD19 in&#xD;
      patients with B-cell non-Hodgkin's lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>To evaluate the safety, tolerability, and determine the recommended dosage of Anti-CD19 CAR-NK Cell Therapy for B-cell Non-Hodgkin Lymphoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The overall response rate(ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To determine the anti-tumor effectivity of CAR-NK019</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To determine the anti-tumor effectivity of CAR-NK019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To determine the anti-tumor effectivity of CAR-NK019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of CAR positive cells</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The copy number of CAR DNA was measured at the preset follow-up time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of CAR-NK cells</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The duration of CAR-positive NK cells in circulation was measured by FACs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>B-cell Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>CAR-NK019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects were intravenously administrated with CAR-NK019</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD19 CAR-NK</intervention_name>
    <description>lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR</description>
    <arm_group_label>CAR-NK019</arm_group_label>
    <other_name>CAR-NK019</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate in this study and sign an informed consent form;&#xD;
&#xD;
          2. Age 18-75 years old, no gender limit;&#xD;
&#xD;
          3. Histologically diagnosed as diffuse large B-cell lymphoma (DLBCL), transforming&#xD;
             follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell&#xD;
             lymphoma (MCL) and other inert B-cells NHL conversion type:&#xD;
&#xD;
               -  Refractory or relapsed DLBCL refers to the failure to achieve complete remission&#xD;
                  after 2-line treatment; disease progression during any treatment, or disease&#xD;
                  stable time equal to or less than 6 months; or disease progression or recurrence&#xD;
                  within 12 months after autologous hematopoietic stem cell transplantation ；&#xD;
&#xD;
               -  Refractory or relapsed MCL must be resistant to or intolerable to BTK inhibitors;&#xD;
&#xD;
               -  Refractory or relapsed indolent B-cell NHL is the failure or recurrence of&#xD;
                  third-line treatment;&#xD;
&#xD;
               -  Previous treatment must include CD20 monoclonal antibody treatment (unless the&#xD;
                  subject is CD20 negative) and anthracyclines;&#xD;
&#xD;
          4. At least one measurable lesion with the longest diameter ≥ 1.5 cm exists;&#xD;
&#xD;
          5. The expected survival period is ≥12 weeks;&#xD;
&#xD;
          6. The puncture section of the tumor tissue was positive for CD19 expression;&#xD;
&#xD;
          7. ECOG score 0-2 points;&#xD;
&#xD;
          8. Sufficient organ function reserve:&#xD;
&#xD;
               -  Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL (upper limit of&#xD;
                  normal value);&#xD;
&#xD;
               -  Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min;&#xD;
&#xD;
               -  Serum total bilirubin and alkaline phosphatase ≤1.5× UNL;&#xD;
&#xD;
               -  Glomerular filtration rate&gt;50Ml/min&#xD;
&#xD;
               -  Cardiac ejection fraction (EF) ≥50%;&#xD;
&#xD;
               -  Under natural indoor air environment, basic oxygen saturation&gt;92%&#xD;
&#xD;
          9. Allow a previous stem cell transplantation&#xD;
&#xD;
         10. The approved anti-B-cell lymphoma treatments, such as systemic chemotherapy, systemic&#xD;
             radiotherapy, and immunotherapy, have been completed for at least 3 weeks before the&#xD;
             study medication;&#xD;
&#xD;
         11. Allow patients who have previously received CAR-T cell therapy and have failed or&#xD;
             relapsed after 3 months of evaluation;&#xD;
&#xD;
         12. Female subjects of childbearing age must have a negative pregnancy test and agree to&#xD;
             take effective contraceptive measures during the trial&#xD;
&#xD;
         13. Two tests for the new coronavirus were negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have a history of allergies to any of the ingredients in cell products;&#xD;
&#xD;
          2. History of other tumors&#xD;
&#xD;
          3. Previously presented with II-IV degree (Glucksberg criteria) acute GvHD or extensive&#xD;
             chronic GvHD; or are receiving anti-GvHD treatment;&#xD;
&#xD;
          4. Have received gene therapy in the past 3 months;&#xD;
&#xD;
          5. Active infections that require treatment (except for simple urinary tract infections&#xD;
             and bacterial pharyngitis), but preventive antibiotics, antiviral and antifungal&#xD;
             infection treatments are allowed;&#xD;
&#xD;
          6. Hepatitis B (HBsAg positive, but HBV-DNA &lt;103 is not an exclusion criterion) or&#xD;
             hepatitis C virus infection (including virus carriers), syphilis and other subjects&#xD;
             with acquired and congenital immunodeficiency diseases, including But not limited to&#xD;
             people living with HIV;&#xD;
&#xD;
          7. According to the New York Heart Association's Heart Function Classification Standard,&#xD;
             it is classified as Grade III or Grade IV.&#xD;
&#xD;
             Impaired subjects;&#xD;
&#xD;
          8. Those who have received anti-tumor therapy in the early stage but the toxic reaction&#xD;
             has not recovered (the CTCAE 5.0 toxic reaction has not recovered to ≤1, except for&#xD;
             fatigue, anorexia, and hair loss);&#xD;
&#xD;
          9. Subjects with a history of epilepsy or other central nervous system diseases;&#xD;
&#xD;
         10. Enhanced CT or MRI of the head showed evidence of central nervous system lymphoma;&#xD;
&#xD;
         11. Have received any other drugs that target CD19;&#xD;
&#xD;
         12. Women who are breastfeeding and unwilling to stop breastfeeding;&#xD;
&#xD;
         13. Any other situation that the investigator believes may increase the risk of the&#xD;
             subject or interfere with the results of the test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbin Qian</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenbin Qian</last_name>
    <phone>+8613605801032</phone>
    <email>qianwb@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbing Qian</last_name>
      <phone>+8613605801032</phone>
      <email>qianwb@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

